GB201901547D0 - Stabilized Fc Fusion protein solutions - Google Patents

Stabilized Fc Fusion protein solutions

Info

Publication number
GB201901547D0
GB201901547D0 GBGB1901547.8A GB201901547A GB201901547D0 GB 201901547 D0 GB201901547 D0 GB 201901547D0 GB 201901547 A GB201901547 A GB 201901547A GB 201901547 D0 GB201901547 D0 GB 201901547D0
Authority
GB
United Kingdom
Prior art keywords
stabilized
fusion protein
protein solutions
solutions
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1901547.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Priority to GBGB1901547.8A priority Critical patent/GB201901547D0/en
Publication of GB201901547D0 publication Critical patent/GB201901547D0/en
Priority to EP20705472.7A priority patent/EP3921340A1/en
Priority to JP2021544796A priority patent/JP2022519570A/ja
Priority to US17/428,341 priority patent/US20220125718A1/en
Priority to PCT/GB2020/050255 priority patent/WO2020161487A1/en
Priority to JP2024174033A priority patent/JP2025020122A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1901547.8A 2019-02-05 2019-02-05 Stabilized Fc Fusion protein solutions Ceased GB201901547D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1901547.8A GB201901547D0 (en) 2019-02-05 2019-02-05 Stabilized Fc Fusion protein solutions
EP20705472.7A EP3921340A1 (en) 2019-02-05 2020-02-05 Stabilized fc fusion protein solutions
JP2021544796A JP2022519570A (ja) 2019-02-05 2020-02-05 安定化Ｆｃ融合タンパク質溶液
US17/428,341 US20220125718A1 (en) 2019-02-05 2020-02-05 STABILIZED Fc FUSION PROTEIN SOLUTIONS
PCT/GB2020/050255 WO2020161487A1 (en) 2019-02-05 2020-02-05 STABILIZED Fc FUSION PROTEIN SOLUTIONS
JP2024174033A JP2025020122A (ja) 2019-02-05 2024-10-03 安定化Ｆｃ融合タンパク質溶液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1901547.8A GB201901547D0 (en) 2019-02-05 2019-02-05 Stabilized Fc Fusion protein solutions

Publications (1)

Publication Number Publication Date
GB201901547D0 true GB201901547D0 (en) 2019-03-27

Family

ID=65996928

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1901547.8A Ceased GB201901547D0 (en) 2019-02-05 2019-02-05 Stabilized Fc Fusion protein solutions

Country Status (5)

Country Link
US (1) US20220125718A1 (enExample)
EP (1) EP3921340A1 (enExample)
JP (2) JP2022519570A (enExample)
GB (1) GB201901547D0 (enExample)
WO (1) WO2020161487A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025084804A1 (ko) * 2023-10-18 2025-04-24 주식회사 엘지화학 Affimer의 안정화 제형 및 그의 제조 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
ES2700925T3 (es) * 2010-01-19 2019-02-20 Hanmi Science Co Ltd Formulaciones líquidas para conjugado de eritropoyetina de acción prolongada
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
US10995130B2 (en) * 2011-07-01 2021-05-04 Biogen Ma Inc. Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
WO2014078627A1 (en) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
KR101419884B1 (ko) * 2012-11-27 2014-07-16 (주)알테오젠 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス．アー． ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物
JP6798882B2 (ja) * 2013-11-29 2020-12-09 アレス トレーディング ソシエテ アノニム ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤

Also Published As

Publication number Publication date
US20220125718A1 (en) 2022-04-28
WO2020161487A1 (en) 2020-08-13
EP3921340A1 (en) 2021-12-15
JP2025020122A (ja) 2025-02-12
JP2022519570A (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
EP3880814A4 (en) FUSION PROTEIN
IL275426A (en) Transgenic FC fusion proteins containing IL-2
SG11202011743SA (en) Fusion proteins comprising progranulin
IL289887A (en) A fusion polypeptide for immunotherapy
EP3743438A4 (en) CYTOKI FUSION PROTEINS
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
EP3502143A4 (en) BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
EP3287470A4 (en) Novel recombinant bi-functional fusion protein and preparation and application therefor
EP3275895A4 (en) Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof
IL271268A (en) A fusion protein that extends half-life
IL276616A (en) Dosage for treatment with IL-22 Fc fusion proteins
EP3512871A4 (en) LONG UNIFORM RECOMBINANT PROTEIN FIBERS
ZA202003845B (en) Fusion proteins
IL290675A (en) Medical protein concentrates
ZA202102533B (en) Fusion protein
EP3601580A4 (en) NOROVIRUS FUSION PROTEINS AND VLPS WITH NOROVIRUS FUSION PROTEINS
ZA202007491B (en) Stable fusion protein formulation
SG11202000775SA (en) Fusion tags for recombinant protein expression
EP3843755A4 (en) FLT3L-BASED CHIMERIC PROTEINS
GB202113559D0 (en) Fusion polypeptide
EP3740501A4 (en) FUSION PROTEIN EXTENSIONS
GB201901547D0 (en) Stabilized Fc Fusion protein solutions
GB201913804D0 (en) Fusion polypeptides
GB202105044D0 (en) Fusion protein
GB201712792D0 (en) Fusion protein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)